SOUTH SAN FRANCISCO, Calif. , Nov. 11, 2019 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that management plans to present at two media events

Data Reinforce Scientific Foundation of ALLO-715 (anti-BCMA) in Multiple Myeloma and ALLO-819 (anti-FLT3) in Acute Myeloid Leukemia SOUTH SAN FRANCISCO, Calif. , Nov. 06, 2019 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the

Initiated ALLO-715 Phase 1 UNIVERSAL Trial in Relapsed/Refractory Multiple Myeloma (MM) Patient Accrual Ongoing for ALLO-501 Phase 1 ALPHA Trial in Relapsed/Refractory Non-Hodgkin Lymphoma ( NHL ) with Data Expected in First Half of 2020 Entered into Exclusive Collaboration with Notch Therapeutics

Collaboration Includes Exclusive Rights and Targets for Initial Applications in Non-Hodgkin Lymphoma, Leukemia and Multiple Myeloma Notch to Receive Upfront Payment, Research Funding and an Equity Investment Plus Development and Commercial Milestones and Royalties on Net Sales SOUTH SAN FRANCISCO,

Conference Call and Webcast Scheduled for 5:30 AM PT/8:30 AM ET SOUTH SAN FRANCISCO, Calif. , Oct. 29, 2019 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today

Collaboration Will Evaluate Charge-altering Releasable Transporter System for mRNA Delivery to T Cells Research Will Be Led by Stanford Researchers Robert Waymouth, Ph.D., Paul Wender , Ph.D. and Ronald Levy , M.D. SOUTH SAN FRANCISCO, Calif. , Sept. 19, 2019 (GLOBE NEWSWIRE) -- Allogene

SOUTH SAN FRANCISCO, Calif. , Sept. 03, 2019 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that management plans to present at the Morgan

ALLO-501 Phase 1 ALPHA Trial in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma ( NHL ) Advances with Five Clinical Trial Sites Open Investigational New Drug (IND) Application Cleared by the U.S. Food & Drug Administration ( FDA ) for ALLO-715 Targeting BCMA for the Treatment of Patients

Dr. Amado’s Addition to the Senior Leadership Team Reunites Him with Former Colleagues in the Pursuit of Novel Immunotherapies SOUTH SAN FRANCISCO, Calif , Aug. 05, 2019 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development

Conference Call and Webcast Scheduled for 5:30 AM PT / 8:30 AM ET   SOUTH SAN FRANCISCO, Calif. , July 29, 2019 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer,